Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1803648 | 0.75 | KCNH2 (0.41) | ALDH1A1SMN1; SMN2MEN1KMT2ANPSR1 | |
| SCHEMBL1805076 | 0.75 | HDAC9 (0.40) | ALDH1A1SMN1; SMN2MEN1KMT2ANPSR1 | |
| SCHEMBL101958 | 0.74 | CYP1A2 (0.56) | CYP1A2CYP2C9ALDH1A1LMNAMEN1 | |
| SCHEMBL1805950 | 0.73 | PDK2 (0.35) | ALDH1A1SMN1; SMN2MEN1KMT2ANPSR1 | |
| SCHEMBL14878640 | 0.72 | ALOX15 (0.46) | CYP1A2CYP2C9SCN9AALDH1A1SMN1; SMN2 | |
| SCHEMBL1809006 | 0.72 | PDE10A (0.33) | ALDH1A1 | |
| SCHEMBL1806040 | 0.72 | HSD11B1 (0.40) | ALDH1A1 | |
| SCHEMBL3646284 | 0.71 | ALDH1A1 (0.48) | CYP1A2CYP2C9SCN9AALDH1A1SMN1; SMN2 | |
| SCHEMBL1807552 | 0.71 | POLB (0.33) | ALDH1A1SMN1; SMN2MEN1KMT2ANPSR1 | |
| SCHEMBL1807042 | 0.70 | OPRL1 (0.41) | ALDH1A1SMN1; SMN2MEN1KMT2ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2501703-B1 | SPIROPIPERIDINE COMPOUNDS AS ORL-1 RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2013-09-18 | — | — | EP | disclosed |
| US-8232289-B2 | Spiropiperidine compounds as ORL-1 receptor antagonists | ELI LILLY AND COMPANY (US) | 2012-07-31 | — | — | US | disclosed |
| US-8232289-B2 | Spiropiperidine compounds as ORL-1 receptor antagonists | ELI LILLY AND COMPANY (US) | 2012-07-31 | — | — | US | disclosed |
| US-8232289-B2 | Spiropiperidine compounds as ORL-1 receptor antagonists | ELI LILLY AND COMPANY (US) | 2012-07-31 | — | — | US | disclosed |
| US-20110118251-A1 | SPIROPIPERIDINE COMPOUNDS AS ORL-1 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2011-05-19 | — | — | US | disclosed |
| WO-2011060035-A1 | SPIROPIPERIDINE COMPOUNDS AS ORL-1 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2011-05-19 | — | — | WO | disclosed |
| US-20110118251-A1 | SPIROPIPERIDINE COMPOUNDS AS ORL-1 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2011-05-19 | — | — | US | disclosed |
| US-20110118251-A1 | SPIROPIPERIDINE COMPOUNDS AS ORL-1 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118251-A1 | SPIROPIPERIDINE COMPOUNDS AS ORL-1 RECEPTOR ANTAGONISTS | OXER1, OGFRL1, ORMDL3 | CYP1A2 591/4885CYP2C9 1217/4885SCN9A 1042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.